Image 1 of 1
Retatrutide – GLP‑3 Peptide (commonly called “Reta”) is a synthetically engineered tri-agonist peptide with high affinity for GLP‑1, GIP, and glucagon receptors.
By simultaneously activating GLP‑1, GIP, and glucagon receptors, Reta allows researchers to explore the complex interplay between multiple metabolic pathways in non-human models. Nicknamed “Triple‑G” for its multi-receptor activity, this peptide surpasses traditional single-pathway molecules, providing a versatile platform for studying energy regulation, nutrient partitioning, and adaptive metabolic responses. Its design facilitates the simultaneous investigation of multiple metabolic signaling cascades, positioning it as a next-generation tool for probing energy homeostasis in preclinical research.
Retatrutide’s molecular architecture delivers enhanced receptor selectivity and prolonged bioactivity, making it ideal for studies on lipid metabolism, glucose flux, and metabolic plasticity. In controlled laboratory settings, it has been shown to influence adipocyte signaling, hepatic substrate cycling, and neuroendocrine feedback pathways in non-human subjects and in vitro assays.
Its distinct pharmacokinetic and pharmacodynamic profile enables researchers to dissect complex regulatory networks governing energy allocation, mitochondrial function, and anabolic/catabolic transitions in animal models and organoid systems. As such, Reta serves as a powerful asset for investigating integrative metabolic control across multiple physiological compartments in non-clinical research.
With its robust pharmacological profile and broad research applications, Retatrutide – GLP‑3 Peptide provides a cutting-edge platform for advancing studies in energy homeostasis and metabolic signaling.